Identification of Novel Mutational Drivers Reveals Oncogene Dependencies in Multiple Myeloma
Overview
Authors
Affiliations
Understanding the profile of oncogene and tumor suppressor gene mutations with their interactions and impact on the prognosis of multiple myeloma (MM) can improve the definition of disease subsets and identify pathways important in disease pathobiology. Using integrated genomics of 1273 newly diagnosed patients with MM, we identified 63 driver genes, some of which are novel, including , , , , and Oncogene mutations are significantly more clonal than tumor suppressor mutations, indicating they may exert a bigger selective pressure. Patients with more driver gene abnormalities are associated with worse outcomes, as are identified mechanisms of genomic instability. Oncogenic dependencies were identified between mutations in driver genes, common regions of copy number change, and primary translocation and hyperdiploidy events. These dependencies included associations with t(4;14) and mutations in , , and ; t(11;14) with mutations in and ; t(14;16) with mutations in , , , and ; and hyperdiploidy with gain 11q, mutations in , and rearrangements. These associations indicate that the genomic landscape of myeloma is predetermined by the primary events upon which further dependencies are built, giving rise to a nonrandom accumulation of genetic hits. Understanding these dependencies may elucidate potential evolutionary patterns and lead to better treatment regimens.
Genomic characteristics and prognostic correlations in Chinese multiple myeloma patients.
Chen X, Luo T, Zhang W, Wang S, Zhu M, He H BMC Med Genomics. 2025; 18(1):50.
PMID: 40087669 DOI: 10.1186/s12920-025-02116-5.
Hosoya H, Carleton M, Tanaka K, Sworder B, Syal S, Sahaf B Nat Commun. 2025; 16(1):1824.
PMID: 39979252 PMC: 11842827. DOI: 10.1038/s41467-025-56486-6.
Current State of Evidence on Definitions and Management of High-Risk Multiple Myeloma.
Mohan Lal B, van Rhee F, Al Hadidi S Curr Oncol Rep. 2025; .
PMID: 39937351 DOI: 10.1007/s11912-025-01639-5.
Yan T, Yan Z, Chen G, Xu S, Wu C, Zhou Q Cancer Imaging. 2025; 25(1):9.
PMID: 39891186 PMC: 11783911. DOI: 10.1186/s40644-024-00821-5.
Moreno Rueda L, Wang H, Akagi K, Dang M, Vora A, Qin L Cell Rep Med. 2025; 6(2):101925.
PMID: 39855192 PMC: 11866523. DOI: 10.1016/j.xcrm.2024.101925.